BCG Bladder Cancer Treatment Reprograms Bone Marrow to Boost Tumor Immunity

This groundbreaking study reveals how BCG (Bacillus Calmette-Guérin) immunotherapy for bladder cancer works through an unexpected mechanism: systemic reprogramming of bone marrow stem cells. BCG has been used for decades to treat bladder cancer, but its mechanism remained unclear.

Researchers used mouse models and human patient samples to track BCG's journey after bladder instillation. They discovered that BCG bacteria travel from the bladder to colonize bone marrow, where they reprogram hematopoietic stem and progenitor cells (HSPCs). This reprogramming creates a lasting change in how these stem cells produce immune cells.

The reprogrammed stem cells generate enhanced myeloid cells—neutrophils, monocytes, and dendritic cells—with superior anti-tumor capabilities. These cells broadly remodel tumor microenvironments, making them more hospitable to T-cell infiltration and activation. The researchers demonstrated that transplanting BCG-reprogrammed stem cells alone was sufficient to confer enhanced tumor immunity in recipient mice.

Crucially, this mechanism synergizes with checkpoint blockade immunotherapy, suggesting combination approaches could be more effective. The study also showed that BCG's effects extend beyond bladder cancer, with reprogrammed immune cells providing protection against tumors in other organs.

This research fundamentally changes our understanding of BCG therapy, revealing it as a systemic treatment that works through "trained immunity"—long-lasting reprogramming of innate immune cells. The findings open new avenues for cancer immunotherapy by targeting hematopoietic stem cells to enhance the innate immune drivers of anti-tumor responses.